FDMT Stock Summary and Trading Ideas (4D Molecular Therapeutics | NASDAQ:FDMT)

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.

As of December 19, 2025, FDMT stock price climbed to $8.76 with 309,623 million shares trading.

FDMT has a beta of 1.09, meaning it tends to be more sensitive to market movements. FDMT has a correlation of 0.05 to the broad based SPY ETF.

FDMT has a market cap of $500.50 million. This is considered a Small Cap stock.

Last quarter 4D Molecular Therapeutics reported $90,000 in Revenue and -$1.01 earnings per share. This fell short of revenue expectation by $-555,800 and missed earnings estimates by -$.01.

In the last 3 years, FDMT traded as high as $36.25 and as low as $2.24.

The top ETF exchange traded funds that FDMT belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

FDMT has outperformed the market in the last year with a return of +46.7%, while the SPY ETF gained +17.2%. In the last 3 month period, FDMT beat the market returning +23.4%, while SPY returned +3.3%. However, in the most recent 2 weeks FDMT has underperformed the stock market by returning -21.7%, while SPY returned -0.6%.

FDMT support price is $8.21 and resistance is $9.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.